SLC46A3 and hepatocellular carcinoma: A recent study has suggested that down-regulation of the SLC46A3 carrier localized at the lysosomal membrane, as other proton-coupled transporters, is involved in sorafenib resistance, and hence can be considered a marker of HCC prognosis and a new therapeutic target [18].